Tandem Diabetes Care opened higher at $18.82, compared with its previous close of $18.77. In the last trading session, the stock traded between $17.51 and $19.20. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Tandem Diabetes Care is now worth
$ 13.06
Resulting in a loss of
$ 86.94 (86.94%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
$-1.26 (-6.71%)
Day High
$19.20
Day Low
$17.51
Day Open
$18.82
Prev Close
$18.77
Volume
17,18,321
1W Return
-8.02%
1M Return
6.39%
3M Return
-25.34%
6M Return
18.56%
1Y Return
-0.05%
Market Cap ($ Mn)
1,222
PE Ratio
-
PB Ratio
11.43
PEG Ratio
-
ROE
-121.88%
ROCE
-31.38%
EPS (TTM)
$-0.10
1 Week
-8.02%
1 Month
6.39%
3 Months
-25.34%
6 Months
18.56%
9 Months
-10.93%
Tandem Diabetes Care Q3FY26 Results: Revenue up 14% YoY to $284 million
Q3FY26 revenue grew 14% YoY to $284 million, with pump shipments up 12%. Gross margin hit a record 57%, up 3 percentage points YoY. CEO John Sheridan announces retirement; Jeanette Bankus to succeed him in November. FY26 sales guidance reaffirmed at $1.065 billion to $1.085 billion. Pharmacy sales reached 15% of US sales, though adoption pace is gradual.
7 days agoTandem Diabetes Care to release Q3FY26 results on November 5, 2026
Tandem Diabetes Care plans to release Q3FY26 results on November 5, 2026. Conference call scheduled for 4:30 pm Eastern Time on the same day. Webcast archive available for 30 days post-event.
1mo agoTandem Diabetes expands Mobi to 12 international markets
Tandem Mobi automated insulin delivery system launched in 12 European countries. System integrates Control-IQ+ algorithm with Dexcom G7 continuous glucose monitor. Android support and Abbott sensor integration planned for select markets in 2027.
1mo agoWilliam Blair initiates coverage on Tandem Diabetes Care with Outperform rating
William Blair initiates coverage on Tandem Diabetes Care with an Outperform rating. Beta Bionics receives a Market Perform rating from William Blair analyst Steven Lichtman. Tandem trades at 1.8x projected 2026 EV/sales, a discount reflecting slower 13% growth. Beta Bionics trades at a 5.3x multiple, justified by rapid channel expansion. Both firms face potential pricing pressure from Medicare competitive bidding in 2028.
2mo agoTandem Diabetes Care Latest Results: Sales guidance affirmed at $1.065B-$1.085B
Tandem Diabetes Care maintains its FY2026 sales guidance at $1.065 billion to $1.085 billion, matching the $1.074 billion market estimate. The unchanged outlook reflects stable operational expectations and aligns with analyst consensus, indicating no significant shifts in the company's revenue trajectory.
3mo agoTandem Diabetes Care Q2 Results: EPS beats, sales miss
Tandem Diabetes Care delivered a mixed Q2 report, beating EPS estimates with a 60.26% improvement in losses while slightly missing sales targets. Revenue grew 5.77% YoY to $254.560M.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Tandem Diabetes Care is now worth
$ 13.06
Resulting in a loss of
$ 86.94 (86.94%)
Note: Past profits do not guarantee future returns.
